https://xyra.us/2026-03-04T23:25:50.569Zweekly1.0https://xyra.us/science/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/science/atrialfibrillation/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/science/budiodarone/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/publications/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/team/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/news/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/news/xyra-announces-issuance-of-us-patent-to-reduce-the-risk-of-heart-failure-or-strokes-by-reducing-the-number-and-duration-of-atrial-fibrillations/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/news/xyra-announces-the-issuance-of-a-fifth-new-us-patent-in-a-series-of-patents-which-protect-the-use-of-budiodarone-in-the-management-of-atrial-fibrillation-till-after-2040/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/news/xyra-announces-fda-label-guidance-for-managing-atrial-fibrillation-with-budiodarone-and-wearable-monitoring-devices/2026-03-04T23:25:50.569Zweekly0.8https://xyra.us/news/xyra-announces-successful-fda-end-of-phase-2-meeting-and-agreement-on-endpoints-for-approval-of-budiodarone-for-the-management-of-atrial-fibrillation/2026-03-04T23:25:50.569Zweekly0.8